Annals of clinical and translational neurology · 2025
Real-World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lin Li-Tsung, Lin Hui-An, Lin Sheng-Feng
Аннотация
OBJECTIVE: Satralizumab, a monoclonal antibody targeting the interleukin-6 receptor, has demonstrated efficacy in clinical trials for neuromyelitis optica spectrum disorder (NMOSD). However, its real-world effectiveness and safety compared to conventional immunosuppressive therapies remain uncertain.
METHODS: We identified patients diagnosed with NMOSD in the TriNetX federated health research platform between January 2018 and April 2024. This international platform was accessed via Taipei Medical University. Patients were followed for 1 month to 3 years. A 1:1 propensity-score matching (PSM) analysis balanced baseline characteristics between the satralizumab and conventional immunosuppressant groups. Risk ratios (RRs) were calculated for relapse risk and safety outcomes, including sepsis, respiratory infection, urinary tract infection, anemia, neutropenia, and mortality.
RESULTS: A total of 220 patients received satralizumab, while 1744 received conventional immunosuppressants. After PSM, 218 patients remained in each group. Satralizumab was associated with a significantly lower relapse risk at 1 month (RR: 0.38, 95% CI 0.21-0.66), 3 months (RR: 0.43, 95% CI 0.28-0.66), 6 months (RR: 0.50, 95% CI 0.33-0.70), 9 months (RR: 0.62, 95% CI 0.46-0.83), 12 months (RR: 0.63, 95% CI 0.47-0.83), 24 months (RR: 0.60, 95% CI 0.42-0.86) and 36 months (RR: 0.52, 95% CI 0.32-0.83). Across all follow-up intervals, numbers needed to treat were consistently between 4 and 9. No significant differences were observed in infection rates, anemia, neutropenia, or mortality between the groups.
INTERPRETATION: Satralizumab demonstrated superior efficacy in reducing NMOSD relapse rates compared to conventional immunosuppressants while maintaining a comparable safety profile.
METHODS: We identified patients diagnosed with NMOSD in the TriNetX federated health research platform between January 2018 and April 2024. This international platform was accessed via Taipei Medical University. Patients were followed for 1 month to 3 years. A 1:1 propensity-score matching (PSM) analysis balanced baseline characteristics between the satralizumab and conventional immunosuppressant groups. Risk ratios (RRs) were calculated for relapse risk and safety outcomes, including sepsis, respiratory infection, urinary tract infection, anemia, neutropenia, and mortality.
RESULTS: A total of 220 patients received satralizumab, while 1744 received conventional immunosuppressants. After PSM, 218 patients remained in each group. Satralizumab was associated with a significantly lower relapse risk at 1 month (RR: 0.38, 95% CI 0.21-0.66), 3 months (RR: 0.43, 95% CI 0.28-0.66), 6 months (RR: 0.50, 95% CI 0.33-0.70), 9 months (RR: 0.62, 95% CI 0.46-0.83), 12 months (RR: 0.63, 95% CI 0.47-0.83), 24 months (RR: 0.60, 95% CI 0.42-0.86) and 36 months (RR: 0.52, 95% CI 0.32-0.83). Across all follow-up intervals, numbers needed to treat were consistently between 4 and 9. No significant differences were observed in infection rates, anemia, neutropenia, or mortality between the groups.
INTERPRETATION: Satralizumab demonstrated superior efficacy in reducing NMOSD relapse rates compared to conventional immunosuppressants while maintaining a comparable safety profile.